Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group hf - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - other antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma ltd - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 micromol

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml

Malta - English - Medicines Authority

actavis group h.f. reykjavikurvegur 78, 220 hafnarfjörður, iceland - irinotecan - concentrate for solution for infusion - irinotecan 20 mg/ml - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - pembrolizumab 50mg - powder for infusion - 50 mg - active: pembrolizumab 50mg excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose - melanoma keytruda is indicated as monotherapy for the treatment of unresectable or metastatic melanoma in adults. keytruda® is indicated for the adjuvant treatment of patients with melanoma with lymph node involvement who have undergone complete resection.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan - concentrate for solution for infusion - irinotecan 20 mg - antineoplastic agents